MannKind (MNKD) Set to Announce Earnings on Thursday

MannKind (NASDAQ:MNKD - Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

MannKind (NASDAQ:MNKD - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.04. The business had revenue of $72.39 million during the quarter, compared to the consensus estimate of $64.81 million. MannKind had a negative return on equity of 11.97% and a net margin of 4.73%. The business's revenue for the quarter was up 48.9% on a year-over-year basis. During the same period last year, the business posted ($0.02) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 1.4 %

Shares of MNKD stock traded up $0.10 on Friday, hitting $7.17. 2,468,913 shares of the stock were exchanged, compared to its average volume of 2,595,796. The firm's 50 day moving average is $6.36 and its two-hundred day moving average is $5.43. MannKind has a one year low of $3.17 and a one year high of $7.30. The firm has a market capitalization of $1.97 billion, a PE ratio of 179.25 and a beta of 1.31.

Insider Activity at MannKind

In other MannKind news, CEO Michael Castagna sold 85,106 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.30, for a total value of $536,167.80. Following the sale, the chief executive officer now directly owns 2,294,836 shares in the company, valued at $14,457,466.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other MannKind news, CEO Michael Castagna sold 85,106 shares of the company's stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.30, for a total value of $536,167.80. Following the transaction, the chief executive officer now directly owns 2,294,836 shares in the company, valued at $14,457,466.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven B. Binder sold 5,055 shares of the firm's stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $5.94, for a total value of $30,026.70. Following the completion of the sale, the executive vice president now directly owns 1,075,026 shares in the company, valued at approximately $6,385,654.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 195,161 shares of company stock valued at $1,229,095. Corporate insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MNKD. Leerink Partnrs upgraded shares of MannKind to a "strong-buy" rating in a research report on Monday, September 9th. Oppenheimer lifted their price objective on shares of MannKind from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Wednesday, August 28th. Finally, Leerink Partners assumed coverage on shares of MannKind in a report on Monday, September 9th. They set an "outperform" rating and a $8.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.67.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.